NEW YORK, July 12, 2017 /PRNewswire/ --
If you want a Stock Review on CRIS, OVAS, RGLS or VNDA then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, benchmark US indices were in mixed colors as the NASDAQ Composite closed the trading session up 0.27%; the Dow Jones Industrial Average ended flat;
On Tuesday, shares in Lexington, Massachusetts headquartered Curis Inc. recorded a trading volume of 353,477 shares. The stock ended the session 1.03% higher at $1.97. The Company's shares have gained 10.67% in the last one month. The stock is trading 4.21% above its 50-day moving average. Moreover, shares of Curis, which engages in the discovery and development of drug candidates for the treatment of human cancers in the US, have a Relative Strength Index (RSI) of 52.50. Free research report on CRIS is available at:
Waltham, Massachusetts headquartered OvaScience Inc.'s stock closed the day 2.10% higher at $1.46. A total volume of 579,490 shares was traded, which was above their three months average volume of 473,120 shares. The Company's shares have advanced 11.45% in the past month. The stock is trading 2.44% above its 50-day moving average. Additionally, shares of OvaScience, which discovers, develops, and commercializes fertility treatment options for women worldwide, have an RSI of 47.36. The complimentary research report on OVAS can be downloaded at:
Shares in San Diego, California headquartered Regulus Therapeutics Inc. recorded a trading volume of 293,923 shares. The stock ended yesterday's trading session 1.69% lower at $0.95. The Company's shares are trading below their 50-day moving average by 27.35%. Furthermore, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 37.87.
On June 13th, 2017, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $5 a share to $2.50 a share. Visit us today and access our complete research report on RGLS at:
Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s stock finished Tuesday's session flat at $16.55 with a total trading volume of 209,874 shares. The Company's shares have advanced 21.25% in the last one month, 22.14% over the previous three months, and 3.76% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 12.26% and 10.15%, respectively. Additionally, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 65.44.
On June 27th, 2017, research firm Piper Jaffray resumed its 'Overweight' rating on the Company's stock, with a target price of $23 per share. Get free access to your research report on VNDA at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All